on SANOFI-AVENTIS (EPA:SAN)
Sanofi obtains European approval for its VaxRabeo vaccine
Sanofi has announced the European Commission's approval of its new rabies vaccine, VaxRabeo. This vaccine is intended for all age groups for pre-exposure and post-exposure prophylaxis. Manufactured using Vero cell technology, VaxRabeo offers improved thermostability and a longer shelf life compared to existing vaccines. Rabies, a deadly disease transmitted through the saliva of infected animals, causes approximately 59,000 deaths annually. This innovative vaccine from Sanofi helps strengthen protection against this disease, thanks to a rigorous clinical program that has demonstrated its safety and efficacy.
R. P.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SANOFI-AVENTIS news